drugset / Trial / NCT00504166
Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women
Phase 4
Completed
53 enrolled
University of California, San Francisco
Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to evaluate the changes in bone structure as determined by magnetic resonance imaging measurements among early postmenopausal women after 24 months of treatment with alendronate, 70 mg once a week as compared to placebo
Timeline
- Start
- 2006-02
- Primary completion
- 2009-03
- Completion
- 2009-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alendronic Acid | Small molecule | 70 mg | — |